drugset / Trial / NCT03896945

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

NCT03896945

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786, as compared with placebo, for the treatment of negative symptoms of schizophrenia.

Timeline

Start
2019-02-15
Primary completion
2023-05-23
Completion
2023-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Deudextromethorphan Unknown Oral
Subject Quinidine Small molecule Oral

Indications